Global Rheumatoid Arthritis (RA) Market Analysis & Drug Forecasts, 2019-2020 & 2029 - Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Global revenues from RA drug sales are expected to grow from $26.2B in 2019 to $29.1B in 2029.

The publisher projects that the global RA marketplace - which, for the purposes of this report, comprises eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia) - will grow at a compound annual growth rate (CAGR) of 1.0% over the 10-year forecast.

Global growth in the RA market will be driven by continued uptake of new products in the IL-6 and JAK inhibitor classes along with the anticipated approval and launch of four pipeline therapies. This growth will be slackened by sales erosion from biosimilars and generic tofacitinib. Over 70% of sales will come from the US; the US has a large population of RA patients (estimated 1.8M diagnosed prevalent cases in 2029) and high price tags for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs).

Biosimilar erosion will temper the growth of the RA market during the forecast period; between 2019 and 2029, biosimilars sales will increase from 5% to 28% of global sales. Due to favorable local regulations and increased access, biosimilar uptake is expected to be the highest in the 5EU; by 2029, the publisher projects that biosimilar sales in 5EU will represent over 45% of its total sales -60% of which will come from sales of adalimumab and etanercept biosimilars.

The publisher expects that despite biosimilar erosion, Pfizer/Amgen's Enbrel and AbbVie's Humira will remain the global sales leaders during the forecast period, amassing combined sales of $12.6B in 2019 and $9.0B in 2029. Sales of Enbrel and Humira are more likely to be protected from biosimilar erosion than Remicade (negative CAGR of 6.8%) mainly due to a lack of biosimilar availability in the US, the largest RA market in the 8MM. Etanercept and adalimumab biosimilars will not be available in the US until 2028 and 2023, respectively.

Although biosimilars may temper the impact of blockbuster biologics, the publisher expects that the growth of the small molecule Janus kinase (JAK) inhibitor class will powerfully shape the RA market of the future. The publisher projects that the JAK inhibitor class will continue to grow significantly over the forecast period, increasing at a CAGR of 7.2%. This growth is expected to be strongest in the 5EU, where the first JAK inhibitors, Pfizer's Xeljanz and Eli Lilly's Olumiant, only became available starting in 2017. The recent global launch of AbbVie's JAK1 inhibitor, Rinvoq, is expected to significantly expand JAK inhibitor market share, bringing in $2.2B in sales by 2029.

The late-stage pipeline for RA consists of three subcutaneously delivered biologics (the TNF inhibitor ozoralizumab, the interleukin 6 [IL-6] inhibitor olokizumab, and the granulocyte-macrophage colony-stimulating factor [GM-CSF] inhibitor otilimab) and one oral kinase inhibitor (the BTK inhibitor fenebrutinib). Key opinion leaders (KOLs) expressed measured enthusiasm for these agents-they welcomed the potential availability of new mechanisms of action but did not think that any of them would be more or even equally effective as JAK inhibitors.

Of these agents, KOLs were the most enthusiastic about GSK's GM-CSF inhibitor, otilimab, expected to achieve global sales of $626.8M by 2029. All together, these four pipeline agents are expected to claim less than 5% of the RA market in 2029, equivalent to about $1.1B.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market from 2019-2029

2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies

2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA Patients

2.4 Late-Stage RA Pipeline Holds Promise But Likely Won't Match the Utility of JAK Inhibitors

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.3 Symptoms and Severity Classifications

5 Epidemiology

5.1 Risk Factors and Comorbidities

5.2 Global and Historical Trends

5.3 Forecast Methodology

5.4 Epidemiological Forecast for RA (2019-2029)

5.5 Discussion

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

6.5 Australia

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the RA Market

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.3 Cost-Effective Therapies

8.4 Personalized Treatment Strategies

8.5 Improved Guidance on Treating RA Patients in Remission

8.6 New Treatment Options for Patients with Refractory RA

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Other Drugs in Development - Kinase Inhibitors

10. Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessments

11. Market Outlook

11.1 Global Markets

11.2 US

11.3 5EU

11.4 Japan

11.5 Australia

Companies Mentioned

• Abbvie Inc
• Ablynx NV
• Amgen Inc
• Asahi Kasei Pharma Corp
• Astellas Pharma Inc
• AstraZeneca Plc
• Biogen Inc
• Bristol-Myers Squibb Co
• Celltrion Inc
• Chugai Pharmaceutical Co Ltd
• Daiichi Sankyo Co Ltd
• Eisai Co Ltd
• Eli Lilly and Co

For more information about this report visit https://www.researchandmarkets.com/r/ba8mff

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900